1st Quarter Results
AstraZeneca 25 April 2024 Q1 2024 results Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery Revenue and EPS summary Q1 2024 % Change $m Actual CER[1]- Product Sales 12,177 15 18 - Alliance Revenue 457 59 59 - Collaboration Revenue 45 66 66 Total Revenue 12,679 17 19 Reported EPS $1.41 21 30 Core[2] EPS $2.06 7